Megan McSweeney

A new transcranial direct current stimulation device received approval from the FDA for an investigational device exemption, prompting a phase 3 trial.

A new trial is testing a first-of-its-kind stem cell therapy for Parkinson disease, using a patient’s own reprogrammed cells to restore lost dopamine function.

Here are highlights from this week in Psychiatric Times, including updates on the BHV-7000 for bipolar disorder trial and a new study on physician suicide rates.

Learn more about the impact birth complications and life factors may have on postpartum depression.

A recent study found that ketamine and transcranial magnetic stimulation show promise in treating treatment-resistant depression in older adults.

A new study found that suicidal ideation and firearm access are the strongest predictors of veteran suicide risk.

A recent study found that female physicians have a 53% higher risk of suicide compared with the female general population.

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

Learn more about recent research into adolescent mental health, including a pilot study testing the use of short-term trauma stabilization techniques with escitalopram.

Recap Psychiatric Times Black History Month coverage, including welcoming a new sports psychiatry section editor and a clinical conversation on using CBT to empower Black patients.

Here are highlights from this week in Psychiatric Times, including a special report on psychiatric symptoms of celiac disease and the potential dangers of cannabis use in older patients.

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

Here are highlights from this week in Psychiatric Times, including trial updates and thoughts on the history of the antimedication movement.

Learn more about the latest research on bipolar disorder, including the impacts of childhood trauma on its development and the correlation between bipolar disorder and cardiovascular risk.

Catch up on coverage from the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update.

Here are highlights from this week in Psychiatric Times, including conference updates and trial news.

A 52-week study presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update offered a promising new approach to schizophrenia treatment.

A 52-week study presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update offered a promising new approach to schizophrenia treatment.

Learn more about the findings from the first 3 EMERGENT trials, and their use in the 4th and 5th trials, presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update.

A pooled analysis of two clinical trials highlights AXS-05’s rapid and sustained effectiveness in reducing depressive symptoms, offering a promising new treatment option for major depressive disorder with a manageable safety profile.

A new phase 2 trial reveals a novel antidepressant delivers rapid symptom relief for major depressive disorder, with patients experiencing significant improvement within just hours of their first dose.

MindMed has announced the dosing of the first patient in its second Phase 3 study of MM120.

Here are highlights from this week in Psychiatric Times, including trial updates and a new approach to treating a surprising condition.

Learn more about the latest research on the impact the endocrine system has on major depressive disorder.

Check out these updates on research including major depressive disorder (MDD).

Here are highlights from this week in Psychiatric Times, including FDA news and a look back at Psychiatric Times through the years.

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

Here are highlights from this week in Psychiatric Times, including FDA approvals and conference coverage.

Here are highlights from this week in Psychiatric Times, including FDA approvals and trial updates.